abstract |
Novel tricyclic compound represented by formula (I): (I) possess a TXA2 biosynthesis inhibiting activity and/or a TXA2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc. |